Thermo-responsive hydrogel for targeted intranasal antifungal delivery

A thermo-responsive hydrogel delivers antifungal amphotericin B intranasally, remaining liquid at room temperature and gelling at body temperature for targeted, controlled release with self-healing and mucoadhesive properties to reduce systemic side effects.

Background

Fungal infections affecting the nasal passages and upper respiratory tract present a significant clinical challenge, largely due to the difficulty of ensuring that therapeutic agents reach the infected areas in effective concentrations. Systemic administration of antifungal drugs often falls short, as it can result in low drug levels at the target site and a heightened risk of severe side effects. There is a clear need for patient-friendly, localized treatment methods that can offer high local concentrations of medication while minimizing overall exposure, thereby reducing the risk of toxicity.

Current treatments, such as high-dose systemic therapies or rudimentary local applications like irrigations and gauze packing, are fraught with limitations. These methods frequently lead to uneven drug distribution, short residence times, and rapid clearance from the mucosal surfaces, which can compromise treatment effectiveness. In addition, the systemic side effects—most notably nephrotoxicity—pose significant health risks. Hence, the existing approaches are often insufficient to safely and effectively manage invasive fungal infections, underscoring the necessity for improved strategies in local drug delivery.

Technology

This technology is a temperature-sensitive hydrogel formulated from a polymer solution that remains liquid at room temperature and quickly transforms into a semi-solid gel as it warms to body temperature. It combines a safe polymer with the antifungal drug amphotericin B carried in lipid-based vesicles, which may be enhanced with hyaluronic acid for improved adherence to nasal tissues. This reversible gelation, driven by natural bonding interactions, ensures that the material can conform closely to the nasal mucosa for effective localized treatment, while also offering self-healing properties and controlled release of the medication.

What distinguishes this approach is its precise, localized delivery that minimizes systemic exposure and the risk of side effects typically associated with high-dose treatments. The design allows the hydrogel to adapt dynamically to temperature changes, reinforcing stability and retention at the target site while facilitating safe clearance. Moreover, the ability to adjust the composition for tailored release rates provides a competitive edge over more conventional drug delivery methods, enhancing both safety and therapeutic efficacy in treating fungal infections.

Benefits

  • Enables localized drug delivery, reducing systemic toxicity and associated side effects such as nephrotoxicity.
  • Transforms from liquid to gel at body temperature, facilitating easy bedside administration and optimal deposition.
  • Exhibits enhanced mucoadhesion to increase the residence time at the nasal mucosa for sustained treatment.
  • Features self-healing and reversible gelation properties, ensuring integrity and safe clearance when necessary.
  • Offers controlled drug release to maintain high local drug concentration and improve therapeutic efficacy.

Applications

  • Intranasal fungal infection treatment
  • Localized antifungal delivery platform
  • Prophylactic nasal antifungal administration
  • Thermo-responsive drug delivery system
  • Mucoadhesive intranasal gel formulation

Additional info

A thermo-responsive hydrogel is formulated with 15–20% w/v Pluronic F127, amphotericin B (crystalline or liposomal), phosphatidylcholine–cholesterol liposomes, and, optionally, hyaluronic acid for enhanced mucoadhesion. At room temperature (~25°C) it remains liquid and rapidly gels at body temperature (28–37°C) via reversible hydrogen and van der Waals bonding, ensuring localized delivery with self-healing, viscoelastic properties. Additional polymers and modifications further customize release kinetics and stability for targeted intranasal fungal infection treatment.